Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 170 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Accelerated radiotherapy Clear all
Terminated Not applicable Interventional Results available

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

NCT00255684
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Rochester
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 30, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 30, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

NCT00450983
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Genetic + 3 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

NCT00003145
View directory record Official record
Conditions
Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
Interventions
Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil, Therapeutic Allogeneic Lymphocytes, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 30, 2026, 9:58 AM EDT
Not listed Phase 2 Interventional

Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer

NCT01333332
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Standard Dose Acclerated Fraction Radiotherapy
Drug · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

NCT00278148
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Erlotinib, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 30, 2026, 9:58 AM EDT
Withdrawn Phase 2 Interventional

Proton Accelerated Partial Breast Irradiation

NCT03940248
View directory record Official record
Conditions
Breast Cancer
Interventions
Proton Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
50 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Not applicable Interventional Results available

Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer

NCT02076074
View directory record Official record
Conditions
Breast Neoplasms
Interventions
accelerated partial breast irradiation
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00060255
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, carboplatin, carmustine, cyclophosphamide, etoposide, melphalan, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 4 Interventional

Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients

NCT00882596
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated partial breast irradiation
Device
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
50 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

NCT05472792
View directory record Official record
Conditions
Breast Cancer, Quality of Life
Interventions
Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 30, 2026, 9:58 AM EDT
No Longer Available No phase listed Expanded access

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00423826
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

NCT00005814
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction

NCT00009789
View directory record Official record
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer

NCT03936478
View directory record Official record
Conditions
Breast Cancer, DCIS, LCIS
Interventions
MRIdian Radiation Treatment Unit
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

NCT05412082
View directory record Official record
Conditions
Locally Advanced Rectal Cancer
Interventions
Intensity-modulated radiation therapy, 5-fluorouracil, Leucovorin, Oxaliplatin, Capecitabine, Accelerated Radiation Therapy, Irinotecan
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Prospective Randomized Study of Accelerated Radiation Therapy (PRART)

NCT04175210
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation therapy - 3 weeks, Radiation therapy - 2 weeks
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Not applicable Interventional

Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

NCT06607406
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Accelerated radiotherapy, Conventional radiotherapy
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

NCT06319027
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate, Magnetic Resonance Spectroscopy, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

NCT00002809
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, sargramostim, therapeutic immune globulin, cyclophosphamide, methotrexate, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Temple University
Other
Eligibility
17 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca

NCT06008158
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions
Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

NCT00002546
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, ifosfamide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
21 Years to 120 Years · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Gatos, California + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 30, 2026, 9:58 AM EDT